Retatrutide
10mg/vial
Triple receptor agonist (GLP-1, GIP, Glucagon) under active investigation for metabolic regulation.
Choose dosage
Price per vial
$149.99
10mg/vial
Concentration
10mg/vial
Warehouse
US Domestic
Product Description
Retatrutide is a novel triple-receptor agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. It is currently the subject of Phase 3 clinical research exploring its potential in metabolic homeostasis and body-composition modulation.
Research Overview
In preclinical and early clinical research, retatrutide has demonstrated potent activity across all three receptor pathways. The glucagon component adds an element of hepatic glucose output regulation not seen in dual GLP-1/GIP compounds, making it a highly differentiated investigational molecule. Research subjects have shown significant modulation of glucose homeostasis markers and adipose tissue distribution. All use is strictly for in-vitro and laboratory research contexts.
Research Applications
Certificate of Analysis (Janoshik)
Research Use Only
This product is intended solely for laboratory research and analytical purposes. Not for human consumption or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.